Back

Mavacamten for symptomatic mid-ventricular obstruction in apical hypertrophic cardiomyopathy

11 May 2026 (12:30 - 12:41)
Organised by: Logo
Congress Presentation Part of: Myosin inhibition in hypertrophic cardiomyopathy: beyond the classic left ventricular outflow tract story Clinical Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Hyejung Choi

Hallym University medical center, Seoul (Korea (Republic of))

3 More presentations in this session

Presentation thumbnail
Mavacamten therapy in hypertrophic obstructive cardiomyopathy revealing severe aortic stenosis: a case highlighting diagnostic complexity
Mrs G. Dumitru Ionescu (Bucharest, RO)
Slides Video
Presentation thumbnail
Expanding the role of myosin inhibition: mavacamten in apical hypertrophic cardiomyopathy with mid-ventricular obstruction
Doctor J. Fernandes Pedro (Lisbon, PT)
Slides Video
Presentation thumbnail
Long-term clinical benefit of mavacamten for hypertrophic cardiomyopathy in a patient with RAF1-associated noonan syndrome
Mrs H. Seghers (Edegem, BE)
Slides Video

Access the full session

Session thumbnail
Myosin inhibition in hypertrophic cardiomyopathy: beyond the classic left ventricular outflow tract story
Video

The Event

Event poster

Heart Failure 2026

11 May 2026 12:30 CET
You may be interested in
thumbnail
Congress Presentation
Expanding the role of myosin inhibition: mavacamten in apical hypertrophic cardiomyopathy with mid-ventricular obstruction
thumbnail
Congress Session
Myosin inhibition in hypertrophic cardiomyopathy: beyond the classic left ventricular outflow tract story
thumbnail
Congress Presentation
Effects of Mavacamten use in a patient with hypertrophic obstructive cardiomyopathy and extremely high resting left ventricular outflow tract gradient

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources